ERBB2 and neoplasm: Therefore, we hypothesized that tumor-supportive macrophages genetically engineered in situ with an ErbB2-specific CAR could exhibit enhanced phagocytic activity against cancerous BSG cells and subsequently initiate locoregional antitumor immunity.